Allogeneic Tumor Cell Vaccination
Type: Life Science & Biotech
Novel approaches for cancer management for adavnced stage melanoma patients are a significant unmet clinical need.
A Novel tool for active immunization of cancer patients by using modified tumor cell lines expressing MHC-I and co-stimulatory molecules.
The cell line platform is based on successful clinical trials led by Prof. Lotem with both autologous and allogeneic melanoma vaccines.
- Allogeneic melanoma cells expressing HLA-matched molecules.
- Improved immunogenicity of melanoma cells in vitro by de novo expression of a key co-stimulatory molecule.
Indications / Applications:
A Novel approach that was tested in clinical trial for high risk or low residual disease melanoma patients – phase I/II Study. The study was designed for patients who had malignant melanoma and following tumor removal are free of disease, or have only very minor residual disease and are at a very high risk of disease recurrence.